Overview of sessions in English

With a total of 27 sessions, the English-language part of the congress covers a range of topics.

Saal Helmholtz 08:30 - 09:45 27.09.2019
Symposien Fr02
Hot Topics in Myopia Research
Myopia is the most common developmental eye disorder in the first decades of life and the biggest risk factor for sight threatening degenerative eye diseases later in life, second only to age. Its prevalence is increasing worldwide affecting now > 80% in Asian and > 40% in Caucasian populations. Myopia usually develops during primary school and its onset and progression are related to environmental factors such as near work, education and lack of day light exposure as well as to genetic factors. Retardation of myopia progression is a major goal, next to understanding its pathophysiology and the mode of action of the various treatment options.
Wolf Lagrèze (Freiburg)
Frank Schaeffel, Sektionsleiter (Tübingen)
Frank Schaeffel, Sektionsleiter (Tübingen)

The solid correlation between myopia in young people and their professional education provides clear evidence for an important role of the visual environment. Current research focuses on visual factors associated with studying like viewing distance, luminance, spectral composition and visual features in the scene. New devices are available to track such variables in children continuously, and new lenses and new visual stimulation paradigms were discovered to inhibit myopia. In addition, the use of low dose atropine is on the rise.

Caroline Klaver (Rotterdam)
José Manuel González-Méijome (Braga)

Optical interventions to reduce myopia progression include the use of spectacle and contact lenses with specific multifocal, bifocal, peripheral gradient and extended depth of focus. Randomized, controlled clinical trials have shown that these devices can reduce myopia progression and axial elongation of the eye by 30 to 60%. This lecture provides an update on the design features of each device, the claimed efficacy, discusses the potential mechanisms of action and specific clinical orientations for prescription.

Wolf Lagrèze (Freiburg)

The positive outcome of the ATOM-2 trial has sparked the world-wide use of low-dose atropine eye drops to retard myopia progression in children. However, data from non-asian populations are sparse and the protective effect on axial length has not been unequivocally shown, even in asian populations. Hence, further RCTs are mandatory. The talk will give an overview of published trails and meta-analyses as well as planned trials.